Tag: glargine

Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial Continuous glucose monitoring (CGM) is a relatively new technology that utilizes a subcutaneously placed sensor to provide readings as often as every 5 minutes. In this randomized controlled trial, CGM...
1. Type 2 diabetic patients at high-risk for cardiovascular events treated with the ultra long-acting insulin degludec experienced cardiovascular events at an incidence noninferior to patients treated with glargine. 2. Patients treated with degludec experienced lower rates of severe hypoglycemic events compared to those treated with glargine. Evidence Rating: 1 (Excellent) Study...
1. The combination of insulin degludec and the GLP1 antagonist, liraglutide, lowered the HbA1c in patients with type II diabetes to a greater extent than up-titration of insulin glargine. 2. Degludec/liraglutide was also associated with less adverse effects, including frequency of hypoglycemic episodes, weight gain, self-reported physical functioning, and overall...